Arbaclofen extended release - Osmotica Pharmaceutical

Drug Profile

Arbaclofen extended release - Osmotica Pharmaceutical

Alternative Names: Arbaclofen extended release tablets (AERT) - Osmotica Pharmaceutical; Ontinua ER; OS-440

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Osmotica Pharmaceutical
  • Class Aminobutyric acids; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Muscle spasticity

Most Recent Events

  • 28 Apr 2017 Osmotica Pharmaceutical suspends participant recruitment in a phase III trial for Muscle spasticity (in patients with Multiple sclerosis) in USA (PO) (NCT02869425)
  • 14 Sep 2016 Adverse events and efficacy data from a phase III trial in Muscle spasticity (in patients with multiple sclerosis) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 14 Sep 2016 Adverse events and efficacy data from a phase III trial in Muscle spasticity (in patients with multiple sclerosis) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top